Diabetes Drug Recall 2020: More Metformin Medication Recalled For Cancer-Causing Ingredient Levels

In a fifth recall for the diabetes drug Metformin, Lupin Pharmaceuticals has recalled Metformin Hydrochloride Extended-Release Tablets because they may contain N-Nitrosodimethylamine (NDMA) - a cancer-causing ingredient in levels higher than acceptable by the U.S. Food and Drug Administration.

The recalled prescription drug is used to improve blood glucose control in adults with Type 2 diabetes Melllitus. It was sold in a 500 mg dosage with a lot number of G901203 and packaged in 60-count bottles with an NDC number of 68180-336-07.

The Metformin tablets were distributed nationwide to wholesalers, distributors, and mail-order pharmacies. Labels of the recalled medication can be viewed here.

Consumers that have been prescribed the affected Metformin tablets are advised to continue taking the medication until an alternative treatment plan has been provided by their physician, pharmacist, or medical provider.

Consumers that have questions about the recall can contact Inmar Rx Solutions, Inc. at 1-855-532-1856, Monday through Friday from 9 a.m. to 5 p.m. EST. Reimbursement can be provided by Inmar with the lot number found on the side of the bottle.

Lupin Pharmaceuticals said it has not received any reports of adverse effects from the recalled Metformin medication.

Other recalls issued for the diabetes drug Metformin were made by Apotex Corp., Teva Pharmaceuticals USA, Inc., Marksans Pharma Limited, and Amneal Pharmaceuticals LLC.